Robin Lester Carhart-Harris (born 31 August 1980) is a British psychopharmacologist who is Ralph Metzner Distinguished Professor in the Department of Neurology at the University of California, San Francisco.

[1] He is noted for brain imaging studies of psychedelic and psychoactive drugs such as LSD, psilocybin, MDMA, and DMT, and research into their therapeutic use in treating psychiatric disorders such as depression.

[1][10][11] Carhart-Harris joined David Nutt at Imperial College London in 2008,[12] and they have been regular collaborators on the use of psychoactive drugs in treating a variety of psychiatric disorders.

[9][17] In 2021, Carhart-Harris relocated to the United States when he was appointed Ralph Metzner Distinguished Professor and Director of the Neuroscape Psychedelics Division in the Department of Neurology at the University of California, San Francisco.

[19] Along with other academic researchers such as Roland R. Griffiths and Matthew W. Johnson of Johns Hopkins University, Robin Carhart-Harris is one of a growing number of scientists credited with rekindling interest in the field.

[29][30] Carhart-Harris believes psychedelics work by "breaking down habits of mind and brain and behavior",[31] causing "a cascade of neurobiological changes that manifest at multiple scales and ultimately culminate in the relaxation of high-level beliefs".